Worldwide Gene Editing Partnering Deals & Agreements, 2010 to 2022 – Trends; Lea… – Press Release


The “Global Gene Editing Partnering Terms and Agreements 2010 to 2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Gene Editing Partnering Terms and Agreements 2010-2022 report provides an understanding and access to the gene editing partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in gene editing dealmaking in the biopharma industry since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to over 400 gene therapy deals
  • The leading gene editing deals by value since 2010
  • Most active gene editing dealmakers since 2010
  • The leading gene editing partnering resources

The Global Gene Editing Partnering Terms and Agreements 2010-2022 report provides an understanding and access to the gene editing partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene editing partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene editing technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene editing agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene editing partnering deals announced since 2010 including financial terms where available…